Inside MedSpa — Daily Brief, 2026-08-24
The few things that actually moved in your field — distilled. The headlines are free. The so-what is for subscribers.
1RHA Redensity Eye gains FDA clearance for infraorbital hollowing
What happenedRevance and Teoxane announced FDA approval of RHA Redensity Eye, a resilient hyaluronic acid filler designed specifically for under-eye hollowing. This is the first HA filler cleared for this indication with real-time imaging guidance.
2Evolus Q2 revenue up 21%; raises 2026 outlook on Jeuveau momentum
What happenedEvolus reported Q2 2026 revenue growth of 21% year-over-year, delivered its third consecutive quarter of positive adjusted EBITDA, and raised full-year 2026 guidance. The company cited strong Jeuveau (prabotulinumtoxinA) adoption and international expansion.
3Allergan SkinMedica program terms changed; rebate/loyalty structure shifted
What happenedThe public SkinMedica/Allergan brand terms page has been updated since last review, signaling a change in manufacturer loyalty and rebate terms. No formal announcement was made.
4Juvéderm Day promotional discount returns; filler pricing pressure continues
What happenedAllergan has relaunched its Juvéderm Day promotional discount campaign, offering significant price reductions on filler products during the promotional window.
5Ultherapy PRIME gains FDA clearance for knee skin tightening
What happenedUltherapy PRIME received FDA approval for microfocused ultrasound treatment of knee laxity and skin texture, expanding the device's cleared indications beyond face and neck.
This is one morning. Get it every morning.
The full brief — what each item means for your business and exactly what to do about it — lands in your inbox twice a week. $20 a month. Never miss the developments and rule changes that matter.
Get the brief — $20/mo